Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

34.26 -0.77 (-2.21%)
Streaming Delayed Price Updated: 3:25 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Via Benzinga
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028
Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027. 
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
Ultragenyx Pharmaceutical's Earnings: A Preview
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning
JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117. 
Via Benzinga
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For February 13, 2025
Via Benzinga
Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views
Via Benzinga
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts
Via Benzinga
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews
Via Benzinga
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
Ultragenyx forecasts 2024 revenue above estimates, highlights confidence in setrusumab trial progress, and outlines plans for regulatory filings in 2025. 
Via Benzinga
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
Via Benzinga
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast
Via Benzinga
Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical
Via Benzinga
Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views
Via Benzinga
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
Via Benzinga
Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
Via Benzinga
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Genomics Stocks That May Transform Personalized Medicine
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. 
Via InvestorPlace
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
Biogen previously decided against opting into Ionis' Angelman program. 
Via Investor's Business Daily
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024
RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.